Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

PACMAN PAncreatic Cancer therapeutic discovery using Monoclonal ANtibodies

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 July 2025 to 30 June 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101208554

What the project is doing

In the project's own words, from its summary on CORDIS.

The PACMAN project aims to develop a novel therapeutic approach for treating pancreatic ductal adenocarcinomas (PDAC), one of the deadliest cancers with limited therapeutic options. The project focuses on targeting an overexpressed cell surface protein in PDAC implicated in tumor proliferation, invasion and migration by driving carcinogenic signaling. This study aims to investigate the ability of a highly specific monoclonal antibody targeting this protein to treat PDAC.

By studying the therapeutic efficacy and unravelling associated biomarkers of treatment response in patient-derived PDAC models, the PACMAN program will provide preclinical proof of concept to treat PDAC with a novel class of monoclonal antibodies. Based on a robust patient-derived data package, this innovative approach provides the perspective for a first-in-class therapy for PDAC, addressing a critical unmet medical need and offering new hope for patients with this aggressive cancer.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI